Phibro Animal Health Corp (PAHC) Stock
Key stats
- Market cap
- $1.43B
- Price / Earnings ratio
- 13.7x
- EPS (TTM)
- $2.54
- Volume
- Loading
- 52-week high
- $60.08
- 52-week low
- $28.25
- Dividend yield
- 1.37%
- Dividend amount (latest)
- $0.12
Source: third-party data provider, as of November 13, 2026
Compare with PAHC
Recent news

Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation Declares Quarterly Dividend
PAHC

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
PAHC

Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
PAHC

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
PAHC
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.83
- MACD 12/26/9
- -0.60
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.56
- SMA 50
- $36.89
- Price below SMA 50
- EMA 50
- $36.84
- Price below EMA 50
- SMA 200
- $41.09
- Price below SMA 200
- EMA 200
- $39.98
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
No data available
Source: third-party data provider
Latest news

Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation Declares Quarterly Dividend
PAHC

Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
PAHC

Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
PAHC

Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
PAHC

Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?
PAHC

PAHC or SYK: Which Is the Better Value Stock Right Now?
PAHC or SYK: Which Is the Better Value Stock Right Now?
PAHC

Is it the Right Time to Add Phibro Stock to Your Portfolio?
Is it the Right Time to Add Phibro Stock to Your Portfolio?
PAHC

PAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC vs. HAE: Which Stock Is the Better Value Option?
PAHC

Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
PAHC

Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report?
PAHC
News tone: automated (AI) classification of the article's content, not a price prediction.
About Phibro Animal Health Corp
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. The Company's Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel M. Bendheim J.D. | CEO, President & Director | 1972 |
| Mr. Jack Clifford Bendheim | Executive Chairman | 1947 |
| Mr. Glenn C. David | Chief Financial Officer | 1972 |
| Mr. Larry L. Miller | Chief Operating Officer | 1964 |
| Ms. Judith A. Weinstein | Senior VP, General Counsel & Corporate Secretary | 1969 |
| Ms. Lisa Ann Escudero | Senior Vice President of Human Resources | 1962 |
| Mr. Ramon Fuenmayor | President South America Region | — |
| Mr. Samson Li | President of Asia Pacific Region | 1972 |
| Mr. Todd Armstrong | President of North American Region | — |
| Ms. Mona Desai | VP & Corporate Controller | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.83
- MACD 12/26/9
- -0.60
- EMA 9 of MACD
- -0.04
- MACD histogram
- -0.56
- SMA 50
- $36.89
- Price below SMA 50
- EMA 50
- $36.84
- Price below EMA 50
- SMA 200
- $41.09
- Price below SMA 200
- EMA 200
- $39.98
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -11.7 | +4.6 | ||||||||||
| 2022 | -7.4 | +10.7 | -4.1 | -12.1 | +6.5 | +2.2 | -0.1 | -25.9 | -13.1 | +6.8 | -17.3 | +6.8 |
| 2023 | +12.7 | -1.1 | -3.8 | +2.8 | -16.2 | +6.0 | +5.2 | -5.9 | -12.0 | -14.3 | -14.3 | +17.3 |
| 2024 | -8.6 | +18.2 | -3.4 | +32.4 | +7.8 | -6.5 | +2.6 | |||||
| 2026 | +5.1 | +13.2 | +1.6 | -6.9 | +8.4 | -9.3 |



